STO-609 – 25 mg

Brand:
Cayman
CAS:
52029-86-4
Storage:
-20
UN-No:
Non-Hazardous - /

STO-609 is a calcium/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively).{24732} It is selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥10,000 ng/ml for all). STO-609 inhibits phosphorylation of CaMKI and AMP-activated protein kinase (AMPK) in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility, in a concentration-dependent manner.{52680} It decreases hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp) expression and cumulative food intake in mice when administered intracerebroventricularly as a 20 μM solution at a continuous rate of 0.5 μL/hour .{52681} STO-609 (3 μg/animal, i.c.v.) increases cortical, striatal, and total infarct volume in a mouse model of focal transient cerebral ischemia induced by middle cerebral artery occlusion (MCAO).{52682}  

 

Available on backorder

SKU: 31358 - 25 mg Category:

Description

A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 μM 0.5 μL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 μg/animal, i.c.v.


Formal name: 7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid

Synonyms: 

Molecular weight: 314.3

CAS: 52029-86-4

Purity: ≥95%

Formulation: A solid